Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Directives From House Range From Antibiotics To Zohydro

This article was originally published in The Pink Sheet Daily

Executive Summary

Draft appropriations committee report instructs FDA to undertake tasks both profound (offer a better accounting of how user fees are spent) and routine (meet with patient communities for specific diseases).

You may also be interested in...



Dalvance Approval Is Durata’s GAIN: First Test Of FDA’s Antibiotics Incentives

Durata has honor of having first drug approved under Qualified Infectious Disease Product designation and gains the benefits of an added five years of market exclusivity.

FDA Secure Supply Chain Pilot Draws Small Group, But Could Serve Globalization Goals

Agency planned for up to 100 participants in program allowing expedited entry of some imports, but only approved 13.

Drug Shortage Analysis Puts FDA At Loggerheads With GAO

GAO says ongoing drug shortages are increasing, but FDA says they are flattening; contrasting definitions of “shortage” produce the disparate results.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS077262

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel